Evidence map›Paper›PMID 41182492›Full record

ArticleDiscover oncology2025

Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma.

Mingzhen Zhou, Juan Zhang, Sihui Zhu, Yan Zhao, Baorui Liu, Jie Shen

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingzhen Zhou *The Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Juan Zhang *The Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Sihui ZhuComprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Yan ZhaoThe Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Baorui LiuThe Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. baoruiliu@nju.edu.cn.
Jie ShenThe Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. shenjie2008nju@163.com.

Funding

Medical Science and Technology Development Foundation of Nanjing YKK22095National Natural Science Foundation of Nanjing University of Chinese Medicine XZR2023075The Hospital Management Research of Jiangsu Province JSYGY-3-2023-618
6 · The paper itself

Abstract

This case report presents the application of FOLactis, a lactic acid bacterium in situ vaccine, in the treatment of a lung adenocarcinoma patient who presented with malignant pleural effusion (MPE). An adult patient diagnosed with lung adenocarcinoma complicated by malignant pleural effusion (MPE) experienced favorable outcomes following the administration of intracavitary infusion of FOLactis, as conventional therapeutic approaches failed to yield satisfactory results. One month after the administration of FOLactis treatment, a subsequent CT examination revealed the complete resolution of malignant pleural effusion (MPE).

Indexed as

BacteriotherapyIntrathoracic immunotherapyLung cancerMalignant pleural effusionSitu vaccine

Identifiers

PMID41182492
PMCPMC12583246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.